Key financial ranges
Market cap · USD equivalent
P/E ratio
Annual revenue · USD equivalent
Revenue growth
Valuation & profitability
Price / sales
Annual net income · USD equivalent
Net profit margin
Cash & debt
Cash · USD equivalent
Total debt · USD equivalent
Net cash · USD equivalent
Debt / revenue
| Company | Market cap | P/E | Revenue | Rev. growth | Net income | Cash | Debt | AI value |
|---|---|---|---|---|---|---|---|---|
| JANXJanux Therapeutics, Inc. | $1.22B | — | $10M | -5.6% | -$113.63M | $27.77M | $20.99M | Fair valued |
| UTIUniversal Technical Institute Inc | $1.22B | 36.0× | $835.62M | +14.0% | $63.02M | $130.06M | $362.54M | Fair valued |
| TNCTennant Co | $1.22B | 70.6× | $1.2B | -6.5% | $43.8M | $76.9M | $391.3M | Fair valued |
| BH-ABiglari Holdings Inc. | $1.22B | — | $395.26M | +9.2% | -$37.49M | $68.39M | $289.33M | Fair valued |
| RDVTRed Violet, Inc. | $1.22B | 67.2× | $90.25M | +20.0% | $13.15M | $49.97M | $2.65M | Overvalued |
| CRVSCorvus Pharmaceuticals, Inc. | $1.21B | — | — | — | — | $18.91M | $728K | Overvalued |
| FUBOFuboTV Inc. | $1.21B | — | $1.62B | +18.6% | -$172.25M | $230.28M | $257.4M | Fair valued |
| OPKOpko Health, Inc. | $1.21B | — | $606.88M | -14.9% | -$225.68M | $300.76M | $51.73M | Fair valued |
| MMIMarcus & Millichap, Inc. | $1.21B | 86.7× | $755.16M | +8.5% | -$1.91M | $153.52M | $74.15M | Fair valued |
| YSSYork Space Systems Inc. | $1.21B | — | $253.53M | +6.5% | -$98.91M | $534M | $177.32M | Fair valued |
| AMRCAmeresco, Inc. | $1.21B | 43.8× | $1.77B | +28.8% | $56.76M | $138.33M | $1.86B | Fair valued |
| SECZSecuritize Corp. | $1.21B | — | $62.15M | +233.5% | -$42.04M | $1 | — | Overvalued |
| CCOClear Channel Outdoor Holdings, Inc. | $1.21B | — | $1.14B | +13.1% | $19.94M | $192.14M | $6.47B | Fair valued |
| ODCOil-Dri Corp of America | $1.21B | 23.2× | $485.57M | +11.0% | $54M | $62.94M | $14.48M | Overvalued |
| ACVAACV Auctions Inc. | $1.2B | — | $759.61M | +19.2% | -$66.14M | $242.26M | $47M | Fair valued |
| BRBRBellring Brands, Inc. | $1.2B | 7.3× | $2.32B | +16.1% | $216.2M | $50.4M | $1.14B | Undervalued |
| STAAStaar Surgical Co | $1.2B | 360.8× | $239.44M | -23.7% | -$80.45M | $148.58M | $35.94M | Overvalued |
| RMIXSuncrete, Inc. | $1.2B | — | $103.66M | -46.8% | $20.46M | $13.7M | $202.48M | Overvalued |
| GLUEMonte Rosa Therapeutics, Inc. | $1.2B | — | $123.67M | +63.5% | -$38.63M | $90.1M | $37.99M | Fair valued |
| CRONCronos Group Inc. | $1.2B | 18.2× | $146.59M | +24.6% | -$9.45M | $467.02M | $1.3M | Undervalued |